FINWIRES · TerminalLIVE
FINWIRES

国际能源署称,各国政府出台更多政策,加大能源安全管理支出。

-- 国际能源署(IEA)周五发布的一份报告指出,自2019年以来,全球各国政府在能源领域的支出增加了一倍多,同时能源相关的立法活动也在此期间显著加强。 这份名为《能源政策状况》的报告称,新增能源支出大多用于基础设施、先进制造业、可再生能源、能源效率以及燃料转换激励措施等方面的长期投资。 IEA表示,能源相关活动的增加反映了近年来一系列全球性冲击,包括尚未解决的中东危机,以及对能源安全和可负担性的日益重视。 报告指出,上个月爆发的新一轮能源危机可能会促使各国政府进一步加大能源政策投入,就像上世纪70年代的危机时期一样。 该报告基于国际能源署全球能源政策中心的数据,该中心追踪了84个国家的6500项政策措施,重点介绍了2025年200多个能源政策领域的变化。 报告指出,各国政府已加大力度关注新型风险,主要是关键矿产和能源技术供应链的集中度。国际能源署追踪的关键矿产政策中,约有三分之一是在过去五年内出台的,其中出口管制尤为突出。 “能源政策正受到一系列复杂且不断变化的全球制约因素的影响,”国际能源署可持续发展、技术和展望主任劳拉·科齐表示。 “各国政府正在采取行动保护消费者、增强能源韧性并确保能源供应,但同时也必须确保短期应对措施不会以牺牲长期能源目标为代价。今天做出的选择很可能对能源系统的未来产生深远影响。” 虽然一些国家加大了提高能源效率和推进燃料转换的力度,但另一些国家,尤其是在公路运输领域,倒退的幅度更大。 国际能源署表示,虽然这减轻了合规负担,但可能会使家庭和企业在更长时间内面临能源价格冲击。

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

$KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

$^AXJO$ASX:COH$ASX:EVT$ASX:NXG$ASX:ORG$ASX:PDN$ASX:RHC$ASX:SX2$ASX:TLX$ASX:TUA$ASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

$BOM:524715$NSE:SUNPHARMA